Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Gastroesophageal Junction Cancer.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Dr. Kristen Marrone is a thoracic medical oncology specialist in Baltimore, caring for patients with lung cancer and esophageal cancer. She is the Program Director of the Hematology/Medical Oncology Fellowship Program at the Johns Hopkins School of Medicine. Dr. Marrone received her undergraduate degree in psychology with a neuroscience concentration from Pennsylvania State University. She earned her M.D. from Drexel University College of Medicine. She completed her residency at Yale-New Haven Hospital and performed a fellowship in medical oncology at Johns Hopkins University School of Medicine. Dr. Marrone joined the Johns Hopkins faculty in 2017. Her research interests include clinical trial development and translational studies focusing on optimization of immunotherapy in oncogene driven non-small cell lung cancer. Dr. Marrone is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, the International Association for Study of Lung Cancer and the Society for Immunotherapy in Cancer. Dr. Marrone is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Russell Hales, M.D., is an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also is director of the thoracic multidisciplinary clinic. His research focuses on reconstructing health delivery models to enhance value and improve clinical outcomes. He also studies the effect of immunotherapy and RT in thoracic tumors. Dr. Hales was awarded an R21 grant to study the use of dynamic MRI in predicting tumor motion in patient with lung cancer. Taken together, his research focuses on optimizing patient outcomes using resources from physics, engineering, biology and health delivery systems. Dr. Hales’ efforts extend beyond radiation oncology and clinical management. He has helped to lead in the thoracic oncology program, which includes 20 faculty members and nearly 50 staff, to help chart a vision for this program’s future. In the last four years, the program has gradually transitioned from The Johns Hopkins Hospital campus to Johns Hopkins Bayview Medical Center. Dr. Hales was tasked to head the building and design committee that worked with architects to create a structure conducive to 21st century oncology care. His work extends beyond the bricks and mortar of the new cancer center today to team development within the thoracic oncology program. Simply put, the thoracic oncology move was designed to conceptualize the transition of care from department-based to disease-based medicine. As such, Dr. Hales has worked to integrate the efforts of specialists in medical oncology, thoracic surgery, interventional pulmonology, pathology and radiology. These experts share a clinical space focused on thoracic malignancies and bring a patient-centered model of care to their group. Dr. Hales graduated from Brigham Young University Summa Cum Laude and Valedictorian in 2001. He attended Johns Hopkins Medicine and graduated with an M.D. in 2005. He trained on the Osler Medical Service and attended residency at Johns Hopkins. He joined the faculty at Hopkins in 2010. Dr. Hales focus in program building, research and clinical endeavors is robust, but he understands the key role of academia in training future leaders in medicine. He has been awarded Teacher of the Year in the department of radiation oncology at Hopkins for three of the last six years. He is a well-respected lecturer and travels nationally to speak at conferences and educational workshops about novel therapies in lung and esophagus cancer. Make A Gift. Dr. Hales is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy.

Dr. Lam treats patients with lung cancer, esophageal cancer, mesothelioma, and other thoracic cancers. He directs the Thoracic Oncology Clinical Research Program and the Esophageal Cancer Research Program at Johns Hopkins. Dr. Lam is a clinical and translational researcher with a focus on cancer genomics, liquid biopsies, and novel immunotherapies such as vaccines and cell therapies. He has been recognized with a Conquer Cancer Foundation/ASCO Career Development Award, an LCFA/IASLC/BMS Young Investigator Award, and as a Gilead Research Scholar. Dr. Lam is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

Dr. K. Ranh Voong specializes in thoracic malignancies, including lung, esophageal, thymic cancers, and mesothelioma. She treats patients at both the Johns Hopkins Thoracic Center of Excellence at Johns Hopkins Bayview and at the Proton Center at Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, IMRT for tumors involving the chest. She is the Principal Investigator on grants from Lung Cancer Research Foundation and Hopkins-Wellspan. She is the Principal Investigator of a prospective study evaluating the immunogenic effects of SABR alone on systemic T cell response in patients with stage I NSCLC. She is the principal investigator of a multi-institutional prospective trial showing that routine review of patient-reported outcome measures informs radiation on-treatment toxicity burden assessment and care delivery. She was the Quality of Life Co-chair of a Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (NRG-LU006). She has been invited to participate in national and regularly lectures on thoracic malignancies and protons for thoracic malignancies therapy. In her research, Dr. Voong is dedicated to improving the outcomes of patients with thoracic malignancies, by exploring avenues to better understand and optimize the delivery of radiotherapy. Dr. Voong is also the Program Director for the Radiation Oncology Residency Program. She mentors residents, medical students. Make A Gift. Dr. Voong is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC).

Dr. Wise is a pulmonary, critical care physician. He is an expert in the diagnosis and treatment of patients with obstructive lung disease, including those with asthma and COPD. He is a consultant for patients with scleroderma and interstitial lung disease. He has expertise in pulmonary physiology and lung function testing. Dr. Wise’s research focus is the conduct of multi-center clinical trials in airway diseases and related translational research. Dr. Wise is the co-director of the Pulmonary T32 Multi-disciplinary Training Program in Pulmonary Disease. Dr. Wise is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Systemic Sclerosis (SSc), Interstitial Lung Disease, Acute Interstitial Pneumonia, and Sarcoidosis.

Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3 year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breath of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. Dr. Yang is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Thymectomy.

Joseph C. Murray, M.D., Ph.D. is an Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins in the Upper Aerodigestive Cancer Division (UAD). He is Co-Director of the Lung Cancer Precision Medicine Center of Excellence (PMCOE) and directs the UAD Immunotherapy Database. Dr. Murray received his undergraduate degree in Molecular Cell Biology from the University of California, Berkeley in 2003. After working in the biotechnology industry, he went on to receive his medical and graduate degree in Interdisciplinary Tumor Biology at Georgetown University School of Medicine in 2015. After completing internship and residency in the Osler Medical Residency Training Program at Johns Hopkins Hospital, he remained at Johns Hopkins to complete his fellowship in Medical Oncology in the Sidney Kimmel Comprehensive Cancer Center. Dr. Murray conducts translational research in cancer genomics, liquid biopsy, and immunology in non-small cell lung cancer. He also has expertise in antibody-based immunotherapy, molecular and cell biology, and bioinformatics. He integrates research through the Lung Cancer PMCOE and UAD Immunotherapy Database to conduct observational clinical studies in real-world populations of patients with thoracic cancer. He cares for patients primarily at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Bayview Medical Center. Dr. Murray is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC).

Dr. Bruce Leff is a professor of medicine at the Johns Hopkins University School of Medicine. He holds a joint appointment in the department of health policy and management in the Johns Hopkins Bloomberg School of Public Health and the Department of Community and Public Health in the Johns Hopkins School of Nursing. Dr. Leff is an internationally recognized leader and researcher in the development, evaluation and dissemination of novel models of care for older adults, including the Hospital at Home, Guided Care, geriatric service line models and medical house call practices. In addition, his research interests extend to issues related to multi-morbidity, performance measurement and case-mix issues. He has a strong interest in health policy issues, is a past Health and Aging Policy Fellow of the American Political Science Association, and has served on multiple technical expert panels for the National Quality Forum, NCQA, and Centers for Medicare and Medicaid Services. An award-winning teacher and mentor, Dr. Leff directed the basic Medicine Clerkship in the School of Medicine until 2021. He is a past-president of the American Academy of Home Care Physicians, past-member of the Board of Regents of the American College of Physicians. He is also past- Chair of the Council of the American Board of Internal Medicine (ABIM), as well as the past-Chair of the ABIM Geriatric Medicine Board. He currently serves on the Board of Trustees of the ABIM Foundation. Dr. Leff received his B.A. from the University of Pennsylvania in 1983 and his M.D. from New York University in 1987. After residency and fellowship training at Johns Hopkins, he served as a medical officer in the US Army in Seoul, Korea, before joining the faculty in the Department of Medicine in 1994. Dr. Leff is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Dementia, Severe Acute Respiratory Syndrome (SARS), Hypertension, and COVID-19.

Dr. McCormack is a pulmonary, critical care physician and Associate Director of the Pulmonary & Critical Care Medicine Division. She is an expert in the diagnosis and treatment of patients with obstructive lung disease, including those with asthma and COPD. She has expertise in pulmonary physiology. She serves as the Medical Director of the Johns Hopkins University Pulmonary Function Laboratory and as the Chair of the American Thoracic Society Pulmonary Function Test Committee. She earned her M.D. from Jefferson Medical College of Thomas Jefferson University and her M.H.S. from the Bloomberg School of Public Health. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in pulmonary and critical care medicine at Johns Hopkins. She was the recipient of the Frederick L. Brancati Excellence in Mentoring Award. She plays an active role in mentoring fellows and junior faculty in the Pulmonary & Critical Care Medicine Division. Dr. Mccormack is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Asthma, Acute Interstitial Pneumonia, Interstitial Lung Disease, and Lung Transplant.

Jonathan Rich is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Rich is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Heart Failure, Hypertension, Type 2 Diabetes (T2D), Heart Transplant, and Lung Transplant.

Ziv Gamliel is a Thoracic Surgeon in Baltimore, Maryland. Dr. Gamliel is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, and Thymectomy.

Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Bone Marrow Transplant. Dr. Forde is currently accepting new patients.

Kevin Chen is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Chen has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, and Squamous Cell Lung Carcinoma.

Charles Padgett is an Oncologist in Baltimore, Maryland. Dr. Padgett is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Adenocarcinoma, Large-Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer. Dr. Padgett is currently accepting new patients.

Katherine Scilla is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Scilla is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Tissue Biopsy. Dr. Scilla is currently accepting new patients.

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Akshar Patel is a Radiation Oncologist in Baltimore, Maryland. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma. Dr. Patel is currently accepting new patients.